Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03288493 · OUTCOME

Phase 2: Evaluate Efficacy Endpoints (MRD)

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) · Source last updated 2024-03-28

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Baseline through Month 24

What was measured

Minimum residual disease negative rate

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
Minimum residual disease negative rate
reporting Status
NOT_POSTED
time Frame
Baseline through Month 24
title
Phase 2: Evaluate Efficacy Endpoints (MRD)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice